December 7, 2021 5:14pm

Although, new sector equity highs were being skimmed as market closed

Pre-open indication results: 7 HITs, 1 MISS

Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public markets investor to a journalist; it is that your life and your bank account are largely tied to your questioning of price targets.

The Dow closed UP +492.40 points (+1.40%); the S&P closed UP +95.08 points (+2.07%) while the Nasdaq closed UP +461.76 points (+3.03%)

 

Henry’omics:

Indexes jumped for a second day, continuing Monday’s positive close as investors seem to down-play the new omicron coronavirus variant and its consequences.

The Nasdaq got back above its 50-day moving average.

Last week, the CBOE volatility index, the VIX fear gauge, Tuesday was reduced to 21.89 after Monday slowed at 27.70 after Friday’s high of 30.96 after Thursday’s 27.95 after Wednesday’s 31.12 and last Tuesday’s 27.19.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Tuesday opened positive at 28 ups/4 downs, 2 flats and 1 acquired, stayed positive at the mid-day at 31/2, 1 flat and 1 acquired, ending with a positive close of 29 up/4 downs, 1 flat and 1 acquired;
  • Monday opened negative at 13 ups/21 downs and 1 acquired, flipped positive at the mid-day at 23/11, 1 flat and 1 acquired, ending with a positive close of 25/9 and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “the cell and gene therapy sector is not through correcting. Keep your eyes on strength of appreciation along with the daily volume.” … https://www.regmedinvestors.com/articles/12214

 

lean pickings. The stem, cell and gene therapy sector has sold off sharply in the past few weeks” …  https://www.regmedinvestors.com/articles/12212

 

Pre-open indication results: 7 HITs: < Biostage (BSTG -$0.20), Mesoblast (MESO +$0.64), Fate Therapeutics (FATE +$6.75), CRISPR Therapeutics (CRSP +$7.27), Global Blood Therapeutics (GBT +$1.45), Regenxbio (RGNX +$0.15), Ionis Pharmaceuticals (IONS +3.07)> and 1 MISS < Pluristem (PSTI +$0.12).

 

The Biostage (BSTG) Chronicles: Tuesday closed down -$0.20 with 2,965 shares traded after Monday closed +$0.21 to $3.21 with 6,466 shares traded after Friday closed flat with 0 shares traded after Thursday closed up +$0.07 with 3,527 shares traded after Wednesday closed up +$0.95 with 2,590 shares traded and last Tuesday closed down again -$0.02 with 2,143 shares traded.

  • NO clinical trial from a one (1) and 3/4-year-old IND and a negligence rejection of insurance coverage reimbursement in a terminal death suit.
  • What’s there to invest in, the “Sword of Damocles” terminal death suit insurance claim rejection hanging over the companies non-going operations?

 

Key Metric - volume

Sector volume INCREASED with 19 of the 29-upside having higher than the 3-month average volume with LOW volume of 1 of 4-downside having higher than the 3-month average volume;

 

Jumping with share pricing momentum (10 of 29):

  • Intellia Therapeutics (NTLA +$16.34 after Monday’s -$0.27),
  • CRISPR Therapeutics (CRSP +$7.27 after Monday’s +$1.03),
  • Fate Therapeutics (FATE +$6.75 after Monday’s -$0.16),
  • Ultragenyx (RARE +$5.55 after Monday’s +$2.88),
  • Alnylam Pharmaceuticals (ALNY +$3.28 after Monday’s +$5.64),
  • Ionis Pharmaceuticals (IONS +$3.07 after Monday’s +$1.11),
  • Editas Medicine (EDIT +$2.90),
  • Vericel (VCEL +$2.24 after Monday’s +$1.81),
  • Sage Therapeutics (SAGE +$2.11),
  • Global Blood Therapeutics (GBT +$1.45 after Monday’s +$0.71),

Hammered in today’s market (4 of 4):

  • Biostage (BSTG -$0.20 after Monday’s +$0.21),
  • bluebird bio (BLUE -$0.06),
  • Brainstorm Cell therapeutics (BCLI -$0.03),
  • Adverum Biotechnologies (ADVM -$0.01),

Closing Flat:

  • 1 ReNeuron (RENE.L) and -1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed up +3.92% and XBI closed up +.98%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -5.29 points or -19.46% at 21.89

 

December, the second month of Q4/21:

Tuesday closed positive with 29 incliner, 4 decliners, 1 flat and 1 acquired

Monday (12/6) closed positive with 25 incliner, 9 decliners and 1 acquired

 

The BOTTOM LINE:  A good session, the oversold were further recognized and appreciated.

Tread lightly, tax selling is upon us!

In any case, I have continued to write … don’t ramp exposure at the current levels.

There's also nothing wrong with standing pat after reducing exposure earlier in the month.

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.